These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. Kelly D; Rose AAN; Muniz TP; Hogg D; Butler MO; Saibil SD; King I; Kamil ZS; Ghazarian D; Ross K; Iafolla M; Araujo DV; Waldron J; Laperriere N; Krema H; Spreafico A Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298857 [TBL] [Abstract][Full Text] [Related]
10. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment. Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors. Sander MS; Stukalin I; Vallerand IA; Goutam S; Ewanchuk BW; Meyers DE; Pabani A; Morris DG; Heng DYC; Cheng T Cancer Med; 2021 Apr; 10(8):2618-2626. PubMed ID: 33724676 [TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience. Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM Melanoma Res; 2018 Dec; 28(6):571-577. PubMed ID: 30067547 [TBL] [Abstract][Full Text] [Related]
13. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342 [TBL] [Abstract][Full Text] [Related]
14. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of cutaneous and uveal melanoma liver metastases. Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254 [TBL] [Abstract][Full Text] [Related]
16. Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study. Vanaken L; Woei-A-Jin FJSH; Van Ginderdeuren R; Deroose CM; Laenen A; Missotten G; Thal DR; Bechter O; Schöffski P; Clement P Acta Oncol; 2023 May; 62(5):480-487. PubMed ID: 37200223 [TBL] [Abstract][Full Text] [Related]